THED: Efficacy of Repetitive Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy on Heroin Dependence

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03922659
Collaborator
(none)
300
1
6
29.1
10.3

Study Details

Study Description

Brief Summary

Heroin dependence is one of most common substance dependence, which brings great burden on health worldwide. Heroin dependence may lead to immunosuppression and cognitive impairments. Once heroin dependence is developed, it will be difficult to recover and easy to relapse. Although many efforts had been made in the treatment of heroin dependence, the annual recurrence of heroin dependence with traditional therapies would be up to 90%. Repetitive transcranial magnetic stimulation (rTMS) on the dorsolateral prefrontal cortex (DLPFC) or cognitive behavioral therapy (CBT) each alone was reported to have some effect on preventing from relapse of substance dependence. In order to test whether combined therapy of high frequency rTMS (hf-rTMS) with CBT is better for preventing from relapse of heroin dependence, we recruit patients with heroin dependence to participate this study. The study is a factorial designed and the patients will be assigned into one of the following six groups randomly: (1) regular treatment (symptomatic treatment) with blank TMS; (2) regular treatment (RT) with blank TMS and CBT; (3) RT with right DLPFC hf-rTMS; (4) RT with right DLPFC hf-rTMS and CBT; (5) RT with left DLPFC hf-rTMS; (6) RT with left DLPFC hf-rTMS and CBT. TMS was given 5 days per week for total 2 weeks using uniform scheme (5 seconds of 10Hz stimulation per train, 30 trains per day with inter-train interval of 20 seconds). CBT will be given once per week for total 8 weeks. The patients will be followed up for 6 months. Recurrence of heroin dependence, duration of abstention, heroin/drug intake, craving for heroin and other cognitive psychological assessments will be recorded and compared among the 6 treatment groups and the efficacy of combined therapy of rTMS with CBT will be evaluated in our study.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
300 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Efficacy of Repetitive Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy on Heroin Dependence
Actual Study Start Date :
Jun 30, 2019
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Regular treatment (symptomatic treatment) with blank TMS

Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Active Comparator: Regular treatment (RT) with blank TMS and CBT

Regular treatment (symptomatic treatment) with blank transcranial magnetic stimulation and cognitive behavioral therapy

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Active Comparator: RT with right DLPFC hf-rTMS

Regular treatment with right dorsolateral prefrontal cortex (DLPFC) high frequency repetitive transcranial magnetic stimulation (hf-rTMS)

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Active Comparator: RT with right DLPFC hf-rTMS and CBT

Regular treatment with right DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Active Comparator: RT with left DLPFC hf-rTMS

Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS)

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Active Comparator: RT with left DLPFC hf-rTMS and CBT

Regular treatment with left DLPFC high frequency repetitive transcranial magnetic stimulation (hf-rTMS) and cognitive behavioral therapy (CBT)

Combination Product: Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Outcome Measures

Primary Outcome Measures

  1. Recurrence of heroin dependence [1 month]

    The rate of relapse of heroin dependence after discharge from hospital

  2. Recurrence of heroin dependence [2 month]

    The rate of relapse of heroin dependence after discharge from hospital

  3. Recurrence of heroin dependence [3 month]

    The rate of relapse of heroin dependence after discharge from hospital

  4. Recurrence of heroin dependence [6 month]

    The rate of relapse of heroin dependence after discharge from hospital

Secondary Outcome Measures

  1. Duration of abstinence [6 months]

    The total time or period without any intake of heroin during follow-ups

  2. Heroin consumption [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Diaries of heroin intake in different time of the follow-ups

  3. Craving for heroin [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Craving assessment for heroin by Heroin Craving Questionnaire (HCQ) ranging from 0 to 175. Higher score of HCQ indicates more desire for heroin.

  4. Craving for heroin [2weeks, 1 month, 2 months, 3 months and 6 months]

    Craving assessment by Visual Analogue Scale (VAS) for heroin desire ranging 0 to 10. Higher score indicates more desire for heroin.

  5. Cognitive assessment [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Cognitive assessment by Montreal Cognitive Assessment (MoCA) ranging from 0 to 30. Lower score indicates worse cognitive function.

  6. Psychological assessment - Anxiety [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Psychological assessment by Generalized Anxiety Disorder-7 (GAD-7) ranging from 0 to 21. Higher score indicates more severer anxiety.

  7. Psychological assessment - Depression [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Psychological assessment by Patient Health Questionnaire-9 (PHQ-9) ranging from 0 to 27. Higher score indicates more severer depression.

  8. Psychological assessment - Sleep [2 weeks, 1 month, 2 months, 3 months and 6 months]

    Psychological assessment by Pittsburgh Sleep Quality Index (PSQI) ranging from 0 to 21. Higher score indicates worse sleep.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Diagnosis as heroin dependence according to DSM-IV criteria

  • No definite history of neurological diseases and psychological problems

  • Volunteer to participate the study, cooperate to be followed up

Exclusion Criteria:
  • Acute withdrawal state and CIWA score > 9

  • With other neurological diseases and psychological problems

  • With ever brain trauma and damage

  • With other psychological medications or other substance dependence

  • With other contraindications to have transcranial magnetic stimulation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong China

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ying Peng, Professor, Director of Department of Neurology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT03922659
Other Study ID Numbers:
  • 2019-12-TMSCBT-H
First Posted:
Apr 22, 2019
Last Update Posted:
Mar 22, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ying Peng, Professor, Director of Department of Neurology, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 22, 2021